FindTrial
Sign In

TD-9855

DRUG4 trials

Sponsors

Theravance Biopharma

Conditions

ADHDAttention-Deficit/Hyperactivity DisorderDrug Drug Interaction (DDI)FibromyalgiaHypotension, OrthostaticMultiple System Atrophy (MSA) With Orthostatic HypotensionNeurogenic Orthostatic HypotensionOrthostatic Hypotension

Phase 1

TD-9855 Mass Balance Study
CompletedNCT01924143
Theravance BiopharmaADHD, Fibromyalgia
Start: 2013-10-31End: 2013-12-31Updated: 2021-01-19
Drug-Drug Interaction (DDI) Study for TD-9855
CompletedNCT03432793
Theravance BiopharmaDrug Drug Interaction (DDI)
Start: 2018-02-28End: 2018-04-21Updated: 2021-01-14

Phase 2

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
CompletedNCT01458340
Theravance BiopharmaADHD, Attention-Deficit/Hyperactivity Disorder
Start: 2011-12-31End: 2013-11-30Updated: 2022-04-04
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
CompletedNCT02705755
Theravance BiopharmaHypotension, Orthostatic, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Neurogenic Orthostatic Hypotension +5
Start: 2017-09-09End: 2018-11-28Updated: 2022-09-26

Related Papers

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial.
2021-10-1720 citations
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Clinical Autonomic Research2021-03-2912 citations
Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain
Clinical Pharmacokinetics2020-08-274 citations